United Therapeutics Corp (UTHR)
376.80
+2.78
(+0.74%)
USD |
NASDAQ |
Nov 04, 16:00
368.11
-8.69
(-2.31%)
After-Hours: 20:00
United Therapeutics Research and Development Expense (Annual): 408.00M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 408.00M |
| December 31, 2022 | 322.90M |
| December 31, 2021 | 540.10M |
| December 31, 2020 | 357.70M |
| December 31, 2019 | 1.183B |
| December 31, 2018 | 357.90M |
| December 31, 2017 | 264.60M |
| December 31, 2016 | 147.60M |
| December 31, 2015 | 245.10M |
| December 31, 2014 | 242.50M |
| December 31, 2013 | 299.35M |
| December 31, 2012 | 173.39M |
| December 31, 2011 | 180.02M |
| Date | Value |
|---|---|
| December 31, 2010 | 165.31M |
| December 31, 2009 | 122.19M |
| December 31, 2008 | 239.18M |
| December 31, 2007 | 83.35M |
| December 31, 2006 | 57.57M |
| December 31, 2005 | 36.05M |
| December 31, 2004 | 30.60M |
| December 31, 2003 | 35.42M |
| December 31, 2002 | 26.78M |
| December 31, 2001 | 32.59M |
| December 31, 2000 | 70.19M |
| December 31, 1999 | 30.70M |
| December 31, 1998 | 11.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
322.90M
Minimum
2022
1.183B
Maximum
2019
562.26M
Average
408.00M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Liquidia Corp | 43.24M |
| Pfizer Inc | 10.68B |
| Tonix Pharmaceuticals Holding Corp | 86.66M |
| Ardelyx Inc | 35.54M |
| Entrada Therapeutics Inc | 99.88M |